Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCN-01 + Topotecan in Relapsed SCLC
NCT00098956Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2005
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 7-hydroxystaurosporine in small cell lung cancer (SCLC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rates (Complete and Partial) up to 5 years. Started Jan 2005; status: completed.
02
Drugs
7-hydroxystaurosporine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00098956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00098956.